February 27, 2015

Epic Pharma on Friday launched two generics: a schedule II pain reliever and a calcium channel blocker. 

February 25, 2015

In 10 years, the percentage of opioid analgesic users who used an opioid analgesic stronger than morphine increased from 17% to 37%, NCHS reported Wednesday. 

February 9, 2015

Daiichi Sankyo on Monday announced that its Savaysa (edoxaban) tablets are now available in pharmacies across the United States. The drug was granted approval from the Food and Drug Administration on Jan. 8 and is used to reduce the risk of stroke and systemic embolism in patients who have a non-valvular atrial fibrillation, as well as for the treatment of deep vein thrombosis and pulmonary embolism, the company said.

February 3, 2015

Zogenix last week announced that the Food and Drug Administration approved a new formulation of the company's Zohydro ER (hydrocodone bitartrate) extended-release capsules, CII.

January 26, 2015

Purdue Pharma on Monday announced the launch of Hysingla ER (hydrocodone bitartrate) extended-release tablets CII. According to the company, the once-daily drug is the first and only hydocodone product to be recognized by the Food and Drug Administration as having properties that deter misuse and abuse via chewing, snorting and injection.

January 14, 2015

Egalet Corp. last week announced the licensing and acquisition of two pain products. Egalet has agreed to license worldwide rights to Oxaydo (oxycodone HCI, USP) tablets for oral use only -CII, the first and only approved immediate-release oxycodone product formulated to deter abuse via snorting from Acura Pharmaceuticals, the company stated.

January 13, 2015

Prasco Labs., Takeda Pharmacuetical Company Limited and Takeda's wholly owned subsidiary Takeda Pharmaceuticals U.S.A. on Tuesday announced that Prasco and TPUSA entered into a distribution and supply agreement for the rights to distribute colchicine tablets, USP, the authorized generic of Colcrys tablets. 

 

December 9, 2014

From 2009 to 2013, the number of Americans using prescription opiates declined 9.2%, yet both the number of opioid prescriptions filled and the number of days of medication per prescription rose more than 8% in that time period. 

December 8, 2014
Kroger and Medicine Shoppe are participating in MediMergent's pilot study of the National Medication Safety, Outcomes and Adherence Program.
December 2, 2014

Teva Pharmaceuticals on Monday announced the introduction and availability of Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate Sublingual Tablets, CIII.

November 20, 2014

Purdue Pharma on Thursday announced that the Food and Drug Administration approved Hysingla ER (hydrocodone bitartrate) extended‐release tablets CII, a once‐daily, single‐entity medication formulated using Purdue’s proprietary extended‐release solid oral platform, Resistec.

November 10, 2014

Greenstone announced the launch of sirolimus tablets. The product is offered in 1-mg and 2-mg dosage strengths in bottles of 100 tablets each. 

October 10, 2014

The Drug Enforcement Administration’s final rule moving hydrocodone combination products from Schedule III to the more-restrictive Schedule II officially went into effect on Monday. 

October 8, 2014

Teva Pharmaceutical Industries on Wednesday announced the initiation of a rolling new drug application submission for hydrocodone bitartrate extended-release tablets.

September 30, 2014

Salix Pharmaceuticals and Progenics Pharmaceuticals announced that the Food and Drug Administration approved Relistor (methylnaltrexone bromide) subcutaneous injection in 12-mg dosage strength to treat constipation in patients taking opioids for chronic, non-cancer pain. 

September 16, 2014

The Food and Drug Administration on Tuesday announced approval for Movantik (naloxegol), a treatment for opioid-induced constipation in adults.

September 5, 2014

Purdue Pharma on Thursday shared results from several studies evaluating its investigational pain medication Hysingla ER.

September 5, 2014

Purdue Pharma on Thursday presented results from two epidemiological studies evaluating the reformulation of OxyContin. 

August 14, 2014

Amneal Pharmaceuticals announced four new additions to its portfolio of generic drugs, which represent multiple therapeutic categories and account for $900 million annually in U.S. sales, the company said, citing data from IMS Health.

August 5, 2014

Lannett Co. on Monday announced that its abbreviated new drug application for oxycodone hydrochloride capsules, 5 mg, has been approved by the Food and Drug Administration.

July 31, 2014

Teva Pharmaceuticals on Thursday announced results for second-quarter 2014, which included revenues of $5 billion, an increase of 2% compared with the same period last year.

July 24, 2014

The Food and Drug Administration approved Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended-release tablets), a long-acting opioid analgesic.

July 8, 2014

Purdue Pharma on Tuesday announced that the Food and Drug Administration has granted priority review designation for the company's once-daily, single-entity hydrocodone bitartrate tablet. 

July 2, 2014

Health care providers wrote 259 million prescriptions for opioid painkillers in 2012 — many more in some states than in others — according to a Vital Signs report released Tuesday by the Centers for Disease Control and Prevention that highlights the danger of overdose.